complete response: Live & Latest News Updates : Vimarsana.com

Galapagos NV: Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

Galapagos showcases innovative approach in hematological

Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic...

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

Soligenix (SNGX) Enters Agreement with EMA on Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023. Company Highlights Durable s

Theralase Technologies Inc.: Theralase Release's 4Q2023 Interim Financial Statements

Theralase(R) Release's 4Q2023 Interim Financial Statements

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Strategic shift prioritizes the development of GLP-1 implants for the treatment of obesity and chronic weight management Positive NPM-115 preclinical weight loss data comparable to semaglutide,...

Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts

Imugene Highlights Recent Achievements and Looks Ahead to

Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, highlighted recent progress across the company's immuno-oncology portfolio....